Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
This randomized trial compared rituximab with cyclophosphamide followed by azathioprine in severe ANCA-associated vasculitis. This noninferiority trial showed that there was no difference at 18 months for the induction and maintenance of remissions between groups.
:
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Nephrology Clinical Trial Results Glomerulonephritis Vasculitis Source Type: research